Business Context and Reporting Period
Company: Zevra Therapeutics, Inc. (ZVRA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Zevra is a commercial-stage biopharmaceutical company focused on rare diseases. Key assets include MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC), OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs), and the partnered ADHD product AZSTARYS. The company also has clinical-stage candidates including celiprolol for Vascular Ehlers-Danlos syndrome (VEDS) and KP1077 for idiopathic hypersomnia.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenue | $20,401 | $3,425 |
| Net Loss | $(3,099) | $(16,622) |
| Loss Per Share (Basic & Diluted) | $(0.06) | $(0.40) |
| Operating Cash Flow | $(8,222) | $(16,165) |
| Cash, Cash Equivalents & Investments | $68,731 | $79,549 |
| Long-Term Debt (Carrying Value) | $60,090 | $59,504 |
| Warrant Liability | $13,030 | $17,804 |
Note: Cash and investments as of March 31, 2025, exclude the $148.3 million net proceeds from the sale of the Priority Review Voucher (PRV) which closed on April 1, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by $17.0 million (496%) to $20.4 million, driven primarily by $17.1 million in sales of MIPLYFFA following its September 2024 FDA approval. OLPRUVA sales were de minimis ($0.1 million).
- Net Loss Reduction: Net loss decreased by $13.5 million to $3.1 million. This improvement was largely due to a $15.1 million reduction in operating loss, offset partially by higher interest expense.
- Expense Shifts:
- R&D: Decreased by $9.0 million to $3.3 million, reflecting reduced spending on the KP1077 Phase 2 study and lower personnel costs.
- SG&A: Increased by $9.6 million to $19.5 million due to personnel costs and professional fees associated with building the commercial organization for MIPLYFFA and OLPRUVA.
- Non-Cash Gains: A $4.9 million gain from the fair value adjustment of warrant and contingent value right (CVR) liabilities reduced the net loss.
Guidance, Outlook, and Risks
- Subsequent Event (PRV Sale): On April 1, 2025, Zevra sold the Priority Review Voucher (PRV) received with MIPLYFFA approval for net proceeds of $148.3 million. This transaction significantly bolsters liquidity but is not reflected in Q1 2025 financial statements.
- Commercial Outlook: Management expects to continue commercializing MIPLYFFA and OLPRUVA. The company plans to submit a Marketing Authorisation Application (MAA) for MIPLYFFA in the EU in H2 2025.
- Debt Covenants: The company has a $100 million term loan facility. Covenants require maintaining a minimum cash balance of $20 million and meeting minimum net product sales thresholds. Interest rates are tied to SOFR plus a spread, with potential reductions if sales targets are met.
- Legal Proceedings: Zevra is engaged in litigation with Commave Therapeutics regarding the AZSTARYS License Agreement. The case is in the discovery phase; no accrual has been made, but significant legal expenses are expected.
- Liquidity: Management believes current cash, the recent PRV proceeds, and operating cash flows are sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- PRV Proceeds Impact: Verify the actual cash impact of the $148.3 million PRV sale on the balance sheet in the subsequent Q2 2025 filing.
- MIPLYFFA Commercialization: Monitor enrollment numbers and reimbursement rates for MIPLYFFA to assess if the company can meet the debt covenant sales thresholds ($100M annual sales target).
- AZSTARYS Litigation: Track the outcome of the dispute with Commave, as it could impact royalty revenue streams and legal expenses.
- Debt Structure: Review the terms of the $100 million term loan, specifically the interest rate floor (4.00%) and the potential for interest-in-kind (PIK) payments.
- French AC Clawback: Monitor the estimated reserve liability for the French expanded access program, which stood at $14.6 million as of March 31, 2025.